Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy

Gabriela D'Amico, Emilia A. Korhonen, Andrey Anisimov, Georgia Zarkada, Tanja Olopainen, René Hägerling, Friedemann Kiefer, Lauri Eklund, Raija Sormunen, Harri Elamaa, Rolf A. Brekken, Ralf H. Adams, Gou Young Koh, Pipsa Saharinen, Kari Alitalo

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The endothelial Tie1 receptor is ligand-less, but interacts with the Tie2 receptor for angiopoietins (Angpt). Angpt2 is expressed in tumor blood vessels, and its blockade inhibits tumor angiogenesis. Here we found that Tie1 deletion from the endothelium of adult mice inhibits tumor angiogenesis and growth by decreasing endothelial cell survival in tumor vessels, without affecting normal vasculature. Treatment with VEGF or VEGFR-2 blocking antibodies similarly reduced tumor angiogenesis and growth; however, no additive inhibition was obtained by targeting both Tie1 and VEGF/VEGFR-2. In contrast, treatment of Tie1-deficient mice with a soluble form of the extracellular domain of Tie2, which blocks Angpt activity, resulted in additive inhibition of tumor growth. Notably, Tie1 deletion decreased sprouting angiogenesis and increased Notch pathway activity in the postnatal retinal vasculature, while pharmacological Notch suppression in the absence of Tie1 promoted retinal hypervasularization. Moreover, substantial additive inhibition of the retinal vascular front migration was observed when Angpt2 blocking antibodies were administered to Tie1-deficient pups. Thus, Tie1 regulates tumor angiogenesis, postnatal sprouting angiogenesis, and endothelial cell survival, which are controlled by VEGF, Angpt, and Notch signals. Our results suggest that targeting Tie1 in combination with Angpt/Tie2 has the potential to improve antiangiogenic therapy.

Original languageEnglish (US)
Pages (from-to)824-834
Number of pages11
JournalJournal of Clinical Investigation
Volume124
Issue number2
DOIs
StatePublished - Feb 3 2014

Fingerprint

Angiopoietins
Growth
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-2
Neoplasms
Blocking Antibodies
Cell Survival
TIE-2 Receptor
Therapeutics
Endothelial Cells
Vascular Tissue Neoplasms
Retinal Vessels
Endothelium
Pharmacology
Ligands

ASJC Scopus subject areas

  • Medicine(all)

Cite this

D'Amico, G., Korhonen, E. A., Anisimov, A., Zarkada, G., Olopainen, T., Hägerling, R., ... Alitalo, K. (2014). Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. Journal of Clinical Investigation, 124(2), 824-834. https://doi.org/10.1172/JCI68897

Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. / D'Amico, Gabriela; Korhonen, Emilia A.; Anisimov, Andrey; Zarkada, Georgia; Olopainen, Tanja; Hägerling, René; Kiefer, Friedemann; Eklund, Lauri; Sormunen, Raija; Elamaa, Harri; Brekken, Rolf A.; Adams, Ralf H.; Koh, Gou Young; Saharinen, Pipsa; Alitalo, Kari.

In: Journal of Clinical Investigation, Vol. 124, No. 2, 03.02.2014, p. 824-834.

Research output: Contribution to journalArticle

D'Amico, G, Korhonen, EA, Anisimov, A, Zarkada, G, Olopainen, T, Hägerling, R, Kiefer, F, Eklund, L, Sormunen, R, Elamaa, H, Brekken, RA, Adams, RH, Koh, GY, Saharinen, P & Alitalo, K 2014, 'Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy', Journal of Clinical Investigation, vol. 124, no. 2, pp. 824-834. https://doi.org/10.1172/JCI68897
D'Amico G, Korhonen EA, Anisimov A, Zarkada G, Olopainen T, Hägerling R et al. Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. Journal of Clinical Investigation. 2014 Feb 3;124(2):824-834. https://doi.org/10.1172/JCI68897
D'Amico, Gabriela ; Korhonen, Emilia A. ; Anisimov, Andrey ; Zarkada, Georgia ; Olopainen, Tanja ; Hägerling, René ; Kiefer, Friedemann ; Eklund, Lauri ; Sormunen, Raija ; Elamaa, Harri ; Brekken, Rolf A. ; Adams, Ralf H. ; Koh, Gou Young ; Saharinen, Pipsa ; Alitalo, Kari. / Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. In: Journal of Clinical Investigation. 2014 ; Vol. 124, No. 2. pp. 824-834.
@article{f09ae99ec3694eac882007a15b3bd28a,
title = "Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy",
abstract = "The endothelial Tie1 receptor is ligand-less, but interacts with the Tie2 receptor for angiopoietins (Angpt). Angpt2 is expressed in tumor blood vessels, and its blockade inhibits tumor angiogenesis. Here we found that Tie1 deletion from the endothelium of adult mice inhibits tumor angiogenesis and growth by decreasing endothelial cell survival in tumor vessels, without affecting normal vasculature. Treatment with VEGF or VEGFR-2 blocking antibodies similarly reduced tumor angiogenesis and growth; however, no additive inhibition was obtained by targeting both Tie1 and VEGF/VEGFR-2. In contrast, treatment of Tie1-deficient mice with a soluble form of the extracellular domain of Tie2, which blocks Angpt activity, resulted in additive inhibition of tumor growth. Notably, Tie1 deletion decreased sprouting angiogenesis and increased Notch pathway activity in the postnatal retinal vasculature, while pharmacological Notch suppression in the absence of Tie1 promoted retinal hypervasularization. Moreover, substantial additive inhibition of the retinal vascular front migration was observed when Angpt2 blocking antibodies were administered to Tie1-deficient pups. Thus, Tie1 regulates tumor angiogenesis, postnatal sprouting angiogenesis, and endothelial cell survival, which are controlled by VEGF, Angpt, and Notch signals. Our results suggest that targeting Tie1 in combination with Angpt/Tie2 has the potential to improve antiangiogenic therapy.",
author = "Gabriela D'Amico and Korhonen, {Emilia A.} and Andrey Anisimov and Georgia Zarkada and Tanja Olopainen and Ren{\'e} H{\"a}gerling and Friedemann Kiefer and Lauri Eklund and Raija Sormunen and Harri Elamaa and Brekken, {Rolf A.} and Adams, {Ralf H.} and Koh, {Gou Young} and Pipsa Saharinen and Kari Alitalo",
year = "2014",
month = "2",
day = "3",
doi = "10.1172/JCI68897",
language = "English (US)",
volume = "124",
pages = "824--834",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy

AU - D'Amico, Gabriela

AU - Korhonen, Emilia A.

AU - Anisimov, Andrey

AU - Zarkada, Georgia

AU - Olopainen, Tanja

AU - Hägerling, René

AU - Kiefer, Friedemann

AU - Eklund, Lauri

AU - Sormunen, Raija

AU - Elamaa, Harri

AU - Brekken, Rolf A.

AU - Adams, Ralf H.

AU - Koh, Gou Young

AU - Saharinen, Pipsa

AU - Alitalo, Kari

PY - 2014/2/3

Y1 - 2014/2/3

N2 - The endothelial Tie1 receptor is ligand-less, but interacts with the Tie2 receptor for angiopoietins (Angpt). Angpt2 is expressed in tumor blood vessels, and its blockade inhibits tumor angiogenesis. Here we found that Tie1 deletion from the endothelium of adult mice inhibits tumor angiogenesis and growth by decreasing endothelial cell survival in tumor vessels, without affecting normal vasculature. Treatment with VEGF or VEGFR-2 blocking antibodies similarly reduced tumor angiogenesis and growth; however, no additive inhibition was obtained by targeting both Tie1 and VEGF/VEGFR-2. In contrast, treatment of Tie1-deficient mice with a soluble form of the extracellular domain of Tie2, which blocks Angpt activity, resulted in additive inhibition of tumor growth. Notably, Tie1 deletion decreased sprouting angiogenesis and increased Notch pathway activity in the postnatal retinal vasculature, while pharmacological Notch suppression in the absence of Tie1 promoted retinal hypervasularization. Moreover, substantial additive inhibition of the retinal vascular front migration was observed when Angpt2 blocking antibodies were administered to Tie1-deficient pups. Thus, Tie1 regulates tumor angiogenesis, postnatal sprouting angiogenesis, and endothelial cell survival, which are controlled by VEGF, Angpt, and Notch signals. Our results suggest that targeting Tie1 in combination with Angpt/Tie2 has the potential to improve antiangiogenic therapy.

AB - The endothelial Tie1 receptor is ligand-less, but interacts with the Tie2 receptor for angiopoietins (Angpt). Angpt2 is expressed in tumor blood vessels, and its blockade inhibits tumor angiogenesis. Here we found that Tie1 deletion from the endothelium of adult mice inhibits tumor angiogenesis and growth by decreasing endothelial cell survival in tumor vessels, without affecting normal vasculature. Treatment with VEGF or VEGFR-2 blocking antibodies similarly reduced tumor angiogenesis and growth; however, no additive inhibition was obtained by targeting both Tie1 and VEGF/VEGFR-2. In contrast, treatment of Tie1-deficient mice with a soluble form of the extracellular domain of Tie2, which blocks Angpt activity, resulted in additive inhibition of tumor growth. Notably, Tie1 deletion decreased sprouting angiogenesis and increased Notch pathway activity in the postnatal retinal vasculature, while pharmacological Notch suppression in the absence of Tie1 promoted retinal hypervasularization. Moreover, substantial additive inhibition of the retinal vascular front migration was observed when Angpt2 blocking antibodies were administered to Tie1-deficient pups. Thus, Tie1 regulates tumor angiogenesis, postnatal sprouting angiogenesis, and endothelial cell survival, which are controlled by VEGF, Angpt, and Notch signals. Our results suggest that targeting Tie1 in combination with Angpt/Tie2 has the potential to improve antiangiogenic therapy.

UR - http://www.scopus.com/inward/record.url?scp=84893859971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893859971&partnerID=8YFLogxK

U2 - 10.1172/JCI68897

DO - 10.1172/JCI68897

M3 - Article

C2 - 24430181

AN - SCOPUS:84893859971

VL - 124

SP - 824

EP - 834

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -